Holen Sie sich die Stockscreener-App
119.72
2.20%
-2.69
Handel nachbörslich:
120.02
0.30
+0.25%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Merck Co Inc Aktie (MRK) Neueste Nachrichten
Merck Announces Third-Quarter 2026 Dividend - pharmiweb.com
Merck Co Inc declares Q3 2026 dividend of $0.85 per share - marketscreener.com
Merck Co Inc Declares Q3 2026 Dividend Of $0.85 Per Share - TradingView
Merck & Co. Inc. stock (US58933Y1055): Key cancer drug momentum after latest Keytruda and Lynparza u - AD HOC NEWS
Merck & Co., Inc. stock (US58933Y1055): 6 billion USD bond deal shifts focus to financing strategy - AD HOC NEWS
3 Dividend Stocks to Hold for the Next 10 Years - The Motley Fool
Merck & Co., Inc. (MRK) Completes $6 Billion Public Offering of Notes - GuruFocus
Legal & General Group Plc Has $2.08 Billion Stock Position in Merck & Co., Inc. $MRK - MarketBeat
Morningstar Investment Management LLC Sells 93,011 Shares of Merck & Co., Inc. $MRK - MarketBeat
RHL Group LLC Makes New Investment in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Holdings Decreased by New Age Alpha Advisors LLC - MarketBeat
Choate Investment Advisors Buys 13,581 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Bought by Fisher Asset Management LLC - MarketBeat
Merck & Co., Inc. stock (US58933Y1055): Key takeaways from the latest Keytruda and pipeline updates - AD HOC NEWS
Genus Capital Management Inc. Takes Position in Merck & Co., Inc. $MRK - MarketBeat
Mondrian Investment Partners LTD Sells 38,085 Shares of Merck & Co., Inc. $MRK - MarketBeat
Smead Capital Management Inc. Sells 196,374 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co Inc (MRK) Stock Price, Trades & News - GuruFocus
Catalyst Funds Management Pty Ltd Buys 22,100 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co. Inc. stock (US58933Y1055): FDA nod for Winrevair reshapes growth story - AD HOC NEWS
Merck & Co., Inc. stock (US58933Y1055): cancer franchise drives outlook after latest Keytruda data - AD HOC NEWS
Merck (MRK) Phase 3 TroFuse-005 Trial for Endometrial Cancer Meets Primary Endpoints - Yahoo Finance
LSV Asset Management Cuts Stake in Merck & Co., Inc. $MRK - MarketBeat
Legato Capital Management LLC Buys 8,759 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. stock (US58933Y1055): oncology momentum and fresh debt deal move MRK - AD HOC NEWS
A Look at Merck & Co Inc (MRK) After 5.6% Gain -- GF Value $118. - GuruFocus
A Look at Merck & Co Inc (MRK) After 5.6% Gain -- GF Value $118.14 vs Price $122.41 - GuruFocus
Research Alert: CFRA Raises Opinion On Shares Of Merck & Co., Inc. To Strong Buy From Buy - Moomoo
US58933YCE3 Bond Price and Chart — FWB:US58933YCE3 - TradingView
AbbVie, Merck, Astra among winners of EU drug recommendations this week - Seeking Alpha
Merck & Co Inc Stock (MRK) Opened Up by 4.50% on May 22: Facts Behind the Movement - TradingKey
Merck & Co., Inc. stock (US58933Y1055): Key cancer drug data and dividend profile in focus - AD HOC NEWS
Merck and Kelun's lung cancer combo bests Keytruda in late-stage trial - Seeking Alpha
Keudell Morrison Wealth Management Invests $1.33 Million in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Bought by Pinnbrook Capital Management LP - MarketBeat
Axxcess Wealth Management LLC Buys 263,633 Shares of Merck & Co., Inc. $MRK - MarketBeat
MRK News | MERCK & CO. INC. (NYSE:MRK) - ChartMill
MRK Stock Quote Price and Forecast - CNN
Merck and Ecolab lead M&A funding charge - GlobalCapital
Moderna, Merck cancer combo cuts melanoma spread risk at five years - Reuters
All Merck Articles - 24/7 Wall St.
Merck & Co., Inc. Balance Sheet – BVL:MRKUS - TradingView
44 WEALTH MANAGEMENT LLC's Merck & Co Inc(MRK) Holding History - GuruFocus
Merck & Co. Inc. stock (US58933Y1055): Keytruda data and Q1 2026 results keep pharma heavyweight in - AD HOC NEWS
Merck & Co. Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Merck & Co. Inc. stock (US58933Y1055): Key takeaways from the latest Keytruda growth and pipeline up - AD HOC NEWS
Merck & Co., Inc. stock (US58933Y1055): Key takeaways after latest Keytruda data and Q1 earnings - AD HOC NEWS
MRK6400123 Bond Price and Chart — FINRA:MRK6400123 - TradingView
Cullen Frost Bankers Inc. Has $22.74 Million Position in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co. Inc. stock (US58933Y1055): Key takeaways after latest Keytruda data and oncology updates - AD HOC NEWS
Merck & Co., Inc. stock (US58933Y1055): Key takeaways after the latest Keytruda and Gardasil updates - AD HOC NEWS
VANGUARD ADVICE SELECT GLOBAL VALUE FUND's Merck & Co Inc(MRK) Holding History - GuruFocus
Handelsbanken Fonder AB Boosts Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Gabelli Funds LLC Cuts Holdings in Merck & Co., Inc. $MRK - MarketBeat
HighTower Advisors LLC Sells 50,990 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. Trade Ideas — LSX:A0YD8Q - TradingView
Merck & Co. Inc. stock (US58933Y1055): Terns deal, oncology pipeline keep focus on growth - AD HOC NEWS
Results Reinforce Merck/Kelun’s Sac-TMT As Major TROP2 Player - Citeline News & Insights
Merck & Co. Inc. stock (US58933Y1055): oncology growth meets new M&A financing - AD HOC NEWS
Merck's drug helps uterine cancer patients live longer in late-stage trial - Reuters
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Business Wire
Merck & Company, Inc. (MRK) Stock Analysis: A Healthcare Giant with a Robust 3.05% Dividend Yield - DirectorsTalk Interviews
MRK Stock Price, Quote & Chart | MERCK & CO. INC. (NYSE:MRK) - ChartMill
Merck & Co., Inc. (MRK) is attracting investor attention: Here is what you should know - MSN
L & S Advisors Inc Increases Stake in Merck & Co., Inc. $MRK - MarketBeat
Canada Post Corp Registered Pension Plan Acquires 35,631 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. stock (US58933Y1055): Keytruda momentum and fresh earnings keep big pharma in focu - AD HOC NEWS
0.09%
0.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):